Sunday 18 October 2026
Export AVIR’s income statement to Excel — free account
Atea Pharmaceuticals, Inc.
AVIR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 6.82% and free cash flow grew 85.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
4.32
0.21
−4.64%
Follow AVIR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 6.12 | 0.00 | — | — | — |
P/S ratio |
— | — | — | — | 2.11 | 0.00 | — | — | — |
Altman Z-Score |
— | — | — | — | 9.33 | 2.38 | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | 19.38 | 5.65 | — | — | — |
P/FCF ratio |
— | — | — | — | 0.00 | 3.04 | — | — | — |
P/Operating CF |
— | — | — | — | (9.82) | 2.83 | — | — | — |
P/B ratio |
— | — | — | — | 1.04 | 1.65 | — | — | — |
Price to Tangible BV |
— | — | — | — | 1.04 | 1.65 | — | — | — |
EV/Sales |
— | — | — | — | (0.07) | 0.00 | — | — | — |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
— | — | — | — | 0.28 | 0.16 | — | — | — |
EV/FCF |
— | — | — | — | 0.28 | 0.16 | — | — | — |
Quick Ratio |
7.59 | 24.44 | 17.86 | 35.00 | 13.44 | 2.71 | 8.90 | 19.60 | — |
Current Ratio |
7.82 | 24.85 | 18.24 | 35.77 | 13.58 | 2.73 | 9.00 | 19.71 | — |
Net Debt/EBITDA |
1.63 | 2.23 | 3.23 | 4.76 | (5.52) | 77.73 | 1.48 | 3.65 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.11 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.83 | 0.80 | 0.63 | 1.04 | (0.72) | (27.11) | 0.91 | 0.87 | — |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.37 | (0.14) | (1.37) | (0.12) | (0.71) | — |
| (44.34%) | (33.88%) | (22.74%) | (17.16%) | 19.27% | (4.39%) | 32.74% | 21.14% | — | |
| (40.61%) | (31.78%) | (21.55%) | (16.10%) | 14.81% | (2.47%) | (127.16%) | 0.00% | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(58.29%) | (37.87%) | (24.31%) | (17.99%) | 16.94% | (2.00%) | (71.91%) | (27.47%) | — |
Average Days of Receivables |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 47.59% | 78.18% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 13.03% | 44.50% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 11.28% | 15.33% | 0.00% | 0.00% | — |
Graham Net Nets |
— | — | — | — | 0.96 | 0.61 | — | — | — |
Graham Number |
— | — | — | — | 16.78 | 0.00 | — | — | — |
Earnings Yield |
— | — | — | — | 16.33% | (1.21%) | — | — | — |
Free Cash Flow Yield |
— | — | — | — | (11.75%) | 32.89% | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 4.24 | 2.25 | 0.00 | 0.00 | — |
Operating CF per Share |
(1.62) | (1.61) | (1.02) | (1.45) | (1.05) | 13.74 | (1.27) | (0.79) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 | 0.00 | — |
Free Cash Flow per Share |
(1.62) | (1.61) | (1.02) | (1.48) | (1.05) | 13.74 | (1.27) | (0.79) | — |
Cash per Share |
3.70 | 5.40 | 6.93 | 7.77 | 9.23 | 39.64 | 2.15 | 3.44 | — |
Shareholders Equity per Share |
3.38 | 5.21 | 6.66 | 7.70 | 8.57 | 25.37 | 1.94 | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
3.38 | 5.21 | 6.66 | 7.70 | 8.57 | 25.37 | 1.94 | 0.00 | — |
Free Cash Flow |
(132.03) | (135.50) | (85.39) | (122.92) | (87.01) | 296.71 | (12.83) | (7.92) | — |
Working Capital |
271.21 | 443.75 | 558.08 | 642.44 | 715.52 | 547.68 | 19.48 | 32.94 | — |
Capital Expenditures |
— | — | — | (1.94) | 0.00 | (0.03) | 0.00 | (0.01) | — |
Net Current Asset Value |
271.21 | 436.55 | 550.68 | 634.79 | 709.59 | 547.65 | 19.38 | 34.70 | — |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Capex to Sales |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
— | — | — | — | 5.35 | 0.00 | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
(9.91) | (13.06) | (11.66) | (3.05) | 1.26 | 0.40 | 0.41 | 0.30 | — |
Cash ROIC |
(22.87%) | (15.16%) | (7.54%) | (9.55%) | (5.90%) | 21.14% | (31.14%) | (22.96%) | — |
Accounts Receivable Turnover |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
8.70 | 4.36 | 3.40 | 3.54 | 2.30 | 0.30 | 0.47 | 0.47 | — |
Average Assets |
389.94 | 529.82 | 630.84 | 719.80 | 818.26 | 442.85 | 11.04 | 0.00 | — |
Average Common Equity |
357.15 | 497.03 | 597.88 | 675.32 | 628.94 | 249.12 | (42.87) | (42.87) | — |
Columns are period end dates